Searched for
BACHUPALLY PLANT
USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unitAurobindo Pharma faces scrutiny. The US FDA inspected its Bachupally, Telangana plant. The inspection occurred between August 25 and Septem...- No observations by US FDA during plant inspection: DRLDr. Reddy's Laboratories announced that the U.S. Food & Drug Administration (FDA) completed a routine Good Manufacturing Practice (GMP) ins...
- Dr Reddy's, Sun Pharma recall drugs in US market: USFDADr Reddy's Laboratories and Sun Pharma are recalling products in the US due to manufacturing issues, as per the latest USFDA Enforcement Re...
- USFDA grants VAI classification to Dr Reddy's R&D centreDr Reddy's Laboratories announced that its Hyderabad-based R&D centre has received Voluntary Action Indicated (VAI) classification from the...
- Dr Reddy's recalls over 8,000 bottles of generic drug in US due to packaging errorDr Reddy's Laboratories is recalling over 8,000 bottles of Tacrolimus capsules from the US market due to a packaging error. The Hyderabad-b...
- Dr Reddy's Lab recalls over 4,000 bottles of generic drug in USNew Jersey-based Dr Reddy's Laboratories Inc, a unit of the company, is recalling the affected lot due to "Presence of one Tacrolimus 1 mg ...
- WEF recognises DRL's Bachupally plant, Cipla's Indore OSD unit as part of Global Lighthouse NetworkA press release from the city-based drug maker said Lighthouses are factories leading the way in Fourth Industrial Revolution (Industry 4.0...
- Dr Reddy's recalls 2,980 bottles of cholesterol lowering drug in USAs per the US Food and Drug Administration's latest Enforcement report, the Hyderabad-based drug major is voluntarily recalling the affecte...
- Aurobindo Pharma drops 5% on USFDA observationsShares of Aurobindo Pharma declined to Rs 605.90.
- 'Fat finger' trade sends Dr Reddy's down 10%This is the second time in this year that stock has seen a sharp drop.
- Dr Reddy’s trims losses after 30% fall in the dayThe Bachupally observations include four repeat points, including one repeated from 2015 and 2017, said Jefferies.
- Dr Reddy’s heading for big trouble: Amit Rajan, Celogen Life SciencesThere are multiple problems ahead of Dr Reddy’s in coming days, says Rajan.
- Dr.Reddys bullish about better sales in Europe in FY19Dr Reddys registered eight per cent growth in revenues form Europe to Rs 822 crore during last year, the Q4 of the Fy 18 revenues from the ...
- After Hours: Dr Reddy's in good spirits; realty bleeds the mostUnitech, JP Associates and Fortis Health emerged as the most active stocks in terms of volume.
- Dr Reddy's Labs rises 4% on receiving EIR for Hyderabad plantThe formulation manufacturing plant-3 Bachupally was issued a form 483 by the USFDA with 11 observations.
- German drug regulator finds dirty rooms in Dr' Reddy's facilityThe inspection was conducted on August 1 at the drug maker's formulation manufacturing unit-2 at Bachupally.
- Price erosion in US impacted Q1 margins: Saumen Chakraborty , Dr Reddy's LabsIf competitions are higher, then definitely it leads to more price erosion but we will have to definitely work on those molecules where com...
- Dr Reddy's gets 11 observations from USFDA for Hyderabad plantThe audit of our formulations manufacturing plant-3 at Bachupally, Hyderabad by the USFDA has been completed today, said Dr Reddy's Lab.
- Dr Reddy's recalls 50,000 bottles of Ondansetron tablets in USDr Reddy's Laboratories Inc is recalling 50,280 bottles of Ondansetron tablets 4 mg in a ongoing recall due to "failed impurities/degradati...
- US FDA inspects Lupin's new plant in IndoreThe US drug regulator has started inspection of Indian drugmaker Lupin’s upcoming plant at Indore last week, a person close to the developm...
Load More
